Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies
- 31 March 2011
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 25 (2), 91-96
- https://doi.org/10.1016/j.blre.2011.01.001
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- TP53 Mutation and Survival in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemiaBlood, 2010
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2010
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study GroupJournal of Clinical Oncology, 2009
- Treatment of fludarabine‐refractory chronic lymphocytic leukemiaCancer, 2009
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood, 2008
- How I treat refractory CLLBlood, 2006
- Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged SurvivalJournal of Clinical Oncology, 2005
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood, 2004
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000